Publications by authors named "Patsy Hinson"
Patients with platinum-resistant or -refractory high-grade serous ovarian cancer (HGSOC) have a poor prognosis, and their management represents a substantial unmet medical need. Preclinical data and results from a phase Ib trial demonstrated the efficacy and tolerability of the combination of the α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib plus the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib in platinum-resistant, non--mutated ovarian cancer. Here, we describe the study design and rationale for the phase III, multicenter, open-label, randomized, active-controlled EPIK-O/ENGOT-OV61 trial investigating alpelisib in combination with olaparib compared with standard-of-care chemotherapy in patients with platinum-resistant or -refractory HGSOC with no germline mutation.
View Article and Find Full Text PDFArticle Synopsis
- Homologous recombination deficiency (HRD) occurs when cells can't repair DNA double-strand breaks effectively, making tumors sensitive to treatments like PARP inhibitors and platinum-based chemotherapy.* -
- The Friends of Cancer Research held discussions among healthcare partners to address the lack of standardized methods for defining and measuring HRD across different diagnostic platforms.* -
- The publication offers insights and recommendations for consistent definitions and measurement practices related to HRD, serving as a guide for scientists, physicians, labs, and patients.*